Jessica Hyman

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo et al. · Clinical Cancer Research · 2014 · 542 citations

Medicine, Oncology, Pharmacology +17

<scp>PD</scp> ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ <scp>PD</scp> ‐1/ <scp>PD</scp> ‐ <scp>L</scp> 1 clinical trials

Jason Madore, Ricardo E. Vilain, Alexander M. Menzies et al. · Pigment Cell & Melanoma Research · 2014 · 392 citations

Medicine, Cancer Biology, Clinical Sciences +17

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Georgina V. Long, Carina Fung, Alexander M. Menzies et al. · Nature Communications · 2014 · 387 citations · Full text

Medicine, Oncology, Pharmacology +17

Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment

James S. Wilmott, Lauren E. Haydu, Alexander M. Menzies et al. · The Journal of Immunology · 2014 · 80 citations · Full text

Medicine, Immunology, Oncology +15

Intrapatient Homogeneity of BRAFV600E Expression in Melanoma

Alexander M. Menzies, Trina Lum, James S. Wilmott et al. · The American Journal of Surgical Pathology · 2013 · 74 citations

Medicine, Oncology, Pathology +17